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Abstract
Background: Including participants in patient and public involvement activities is increasingly acknowledged as a
key pillar of successful research activity. Such activities can influence recruitment and retention, as well as researcher
experience and contribute to decision making in research studies. However, there are few established methodologies
of how to set up and manage participant involvement activities. Further, there is little discussion of how to do so when
dealing with collaborative projects that run across countries and operate in multiple linguistic and regulatory contexts.
Methods: In this paper we describe the set-up, running and experiences of the EPAD participant panel. The EPAD
study was a pan-European cohort study with the aim to understand risks for developing Alzheimer’s disease and build
a readiness cohort for Phase 2 clinical trials. Due to the longitudinal nature of this study, combined with the enrolment
of healthy volunteers and those with mild cognitive impairments, the EPAD team highlighted participant involvement
as crucial to the success of this project. The EPAD project employed a nested model, with local panels meeting in
England, France, Scotland, Spain and The Netherlands, and feeding into a central study panel. The local panels were
governed by terms of reference which were adaptable to local needs.
Results: The impact of the panels has been widespread, and varies from feedback on documentation, to supporting
with design of media materials and representation of the project at national and international meetings.
Conclusions: The EPAD panels have contributed to the success of the project and the model established is easily
transferable to other disease areas investigating healthy or at-risk populations.
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Plain English summary
This paper reports on the set up, running and experi-
ences of patient and public involvement in a European
dementia prevention study. The European Prevention of
Alzheimer’s Dementia (EPAD) project was set up to
understand more about risks for developing dementia in
people with no or mild symptoms, and to create a group
of people who would be willing to join drug studies
looking to prevent the development of dementia. Patient
and public involvement was identified as an important
part of EPAD from the outset as it asked for long term
commitment from a group of people who were ‘at risk’
for a disease rather than having the disease of interest.
To achieve this EPAD set up a series of ‘participant
panels’ in England, France, Scotland, Spain and The
Netherlands. These panels were formed from groups of
participants in the study who met at least twice a year
with researchers to provide feedback on their study
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experiences, study paperwork and contribute to study
planning. The panels fed into a central study panel who
met once a year for overall input into the study. The
paper describes how participants were invited to join the
panels as well as how the meetings were organised.
Panels successfully contributed to study documents,
study videos and presenting at national and international
meetings. The panels were an important part of the suc-
cess of the EPAD project and we suggest the set up
would be easy to replicate in other studies.
Introduction
The importance of patient and public involvement in
health care research has been increasingly acknowledged
over the last 25 years [1, 2]. Compared to participation
or engagement, involvement means patients and the
public taking an active role in the shaping of research in
partnership with researchers. More recently, these ‘PPI’
activities have been complemented by new roles for par-
ticipants themselves in shaping and guiding the develop-
ment and conduct of studies.
Opportunities for public and patient involvement
range from involvement in the commission and design
of research ideas through to involvement in the active
process of managing the research study as well as dis-
semination of findings. Review bodies such as the UK
based Health Research Authority (HRA) and many fund-
ing bodies strongly encourage such PPI activities as part
of a applications, and the INVOLVE network has been
established in the UK to support integration of PPI into
health and social research [3, 4]. However, while PPI ini-
tiatives are well established in the UK, there is less ex-
perience in many other European countries, although
patient-run charities, for example, have been influential
partners in setting research agenda, and recent initiatives
such as EUPATI aim to develop opportunities for pa-
tient involvement in clinical trials and health technology
assessment [5–8]. In the case in dementia research, a
scoping review of European PPI activities in dementia
research, found that they were concentrated in the UK,
with 19 projects identified, compared with 1 from the
Netherlands and none elsewhere [4]. Since then, a
framework has been published by the MOPEAD consor-
tium, based in Spain, focussed primarily on the recruit-
ment and retention of participants [9].
The literature on PPI identifies four areas of impact;
on the individual, the research, the researchers and soci-
etal benefit [10].PPI involvement has been linked to ben-
efits in securing funding [11], modest effects on
recruitment [12, 13] and an increased retention [14], as
well as benefiting researchers [15] and funders [16]. The
INVOLVE network have identified examples of real
world benefit to studies incorporating PPI, with quality
the overarching benefit influencing areas ranging from
the relevance of the research topic to the implementa-
tion and impact of research [17]. Interestingly, a study in
the primary care setting found researchers perceived the
most positive impact of PPI when the approach included
more indicators of good practice such as offering train-
ing to contributors [13]. However, despite the number of
frameworks described, researchers often feel unequipped
in knowing how best to involve patients and members of
the public and what benefits they might reasonably ex-
pect [18].
While PPI in general is well established, and may in-
volve long term partnerships between researchers and
lay members, there is growing interest in including the
perspective of those currently taking part in biomedical
research on a systematic and ongoing rather than an ad
hoc basis [19, 20]. Dillon et al. for example, in mapping
the impact of patient engagement in research, describe
the importance of anticipating participant issues, with
the benefits described above, but do not consider poten-
tial active roles for participants themselves [21]. It has
been suggested that the experience and expertise of par-
ticipants directly affected by research activities as well as
the wider public and patient community, can “contribute
knowledge and ethical perspectives highly relevant to re-
search decisions” [22] that can improve the success of
the research project. Participant perspectives are thus
being incorporated throughout the research process,
ranging from decisions about data access [23] to the es-
tablishment of ‘participant panels’ in a range of longitu-
dinal or large-scale studies, including the ALSPAC study
[24], the UK’s 100,000 Genomes project [25] and the US
AllofUs precision medicine initiative [26]. However,
there has been little discussion of how such participant,
patient and public involvement, or PPPI (3PI) can work,
or what difference it can make.
This paper presents the experience of the European
Prevention of Alzheimer’s Dementia (EPAD)
programme with establishing and running panels of
research participants across multiple European coun-
tries. EPAD was a pan-European initiative aiming to
better understand the early stages and risks of devel-
oping Alzheimer’s disease, at the same time develop-
ing a platform to run innovative interventional trials
to test new compounds [27, 28]. The project recruited
over 2000 participants in 11 countries throughout
Europe, with annual visits to the research centres to
complete a range of physical and psychological assess-
ments (with a 6 month visit in year 1 to evaluate cog-
nitive function). Participants were seen in the
longitudinal cohort study (LCS) for up to 4 years of
clinic visits. Participants eligible to enrol in EPAD
LCS were cognitively healthy or have mild cognitive
impairment (MCI), were generally fit and well, had
someone to attend as a study partner and were
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willing in principle to consider enrolment into a clin-
ical trial of an investigational medicinal product.
One of the founding goals of the EPAD programme
was to involve participants as research partners. As with
much PPI activity, this was a result of multiple and over-
lapping motives [2](ref). it reflected a desire to learn
from the experience of participants to improve the
study, thereby increasing successful retention, but also a
normative drive to reciprocate participants’ fundamental
contribution to the project, and to ensure that those
most directly affected by changes to the project were
represented in discussion and decision-making.
Responsibility for planning participant involvement ac-
tivities was identified at the outset of the project as a key
task for the ethics workgroup in EPAD, and resources
were allocated to the development of these activities at
the outset of the project. This planning work built on
learning from patient and public involvement work dur-
ing the project setup with members of the public and
patient groups [29], completed in collaboration with Alz-
heimer Europe and the European Working Group of
People with Dementia, and building on the success of
previous participant involvement activities [30, 31]. The
scope of for potential participant input identified in this
work included but was not limited to study design, un-
derstanding the research experience, input on communi-
cations and future planning.
In this paper we describe the approach to setting up
both the country level and project wide participant
panels, the impact participant involvement has had on
the project and how the model developed in EPAD
could be used by other research fields. The paper draws
on the reflections on researchers and research partici-
pants on the experience of being involved in designing,
setting up and participating in the panels. It draws on
reports from study staff at each centre with a currently
operating panel, study documents related to the panel
developed by the EPAD ethics workgroup, and feedback
from panellists in each local participant panel. This
paper was written in line with the GRIPP2 guidelines,
with additional information available in the GRIPP2
short form checklist [see additional file 1].
Methods
We asked two sets of questions (one to researchers
and one to participant panel members) to gather data
on the set up, running and perceived impact of the
panels. Researchers were asked to reflect on their ex-
perience of recruitment and set up, running of the
panel (primarily focusing on logistical and operational
issues), the content of the panel and the impact of
panel discussions on the study so far. Panel members
were asked a series of questions about their experi-
ences and to reflect on the following areas: their
expectations before joining the panel, in their words
how does the panel they sit on operate, what do they
think the panel has achieved and any other comments
they wished to add. At least one researcher from each
panel contributed to answering the questions about
the panel and are included as co-authors on this
paper. At least one panel member from each panel
contributed answers. The Scottish and Spanish panels
were able to circulate the questions to the entire
panel and the panel member co-authors led on col-
lecting and synthesising this data.
Results
The panel structure and the central panel
The EPAD panel set-up drew upon the experience of
the PREVENT Dementia Study [30]. Key features of the
EPAD participants’ panels included a nested panel struc-
ture, in which multiple local panels function independ-
ently (Fig. 1). Nominated members from these local
panels then formed a single study wide panel, termed
the central panel. Nominations for membership to the
central panel were by peers within the panel, with no
staff involvement. This central panel met in 2018 and
2019, at the General Assembly of the project.. The cen-
tral panel meeting was chaired by the EPAD Ethics
group and was closed to other members of the consor-
tium unless specifically invited by the panel members.
The structure of each panel is described below, with an
overview of the structure provided in Table 1 for
comparison.
Central panel
The central panel meeting had two main goals – to
co-ordinate activities across the local panels, and to
provide for direct participant input into the develop-
ment of the study. Participation in the General As-
sembly provided the opportunity for participants to
learn about the progress of the study, to input into
the primary decision-making body of the consortium,
and to provide feedback through both plenary and
closed meetings. The latter were formally chaired by
the EPAD ethics workgroup, although informal break-
out meetings were also convened by panellists them-
selves to enable learning across different countries’
panel experiences.
Meetings of the central panel took place in 2018
and 2019, with six and ten members respectively at-
tending both the panel meeting and the General As-
sembly. In addition, one participant representative
attended the 2017 project General Assembly, at which
point only the Scottish panel had been established.
Consequently, no central panel was held during this
meeting. During the central panel members could dis-
cuss items that had arisen during their local panels,
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raise topics for discuss and discuss agenda items in-
troduced by the EPAD staff. Panel members then fed
back on their experiences from the central panel and
General Assembly attendance at local panel meetings.
In addition to meetings of the central panel, partici-
pant panel members have also contributed to the
planning of the future direction of the project as it
approaches the end of its initial funding. Participant
panel members from two EPAD countries worked
with the research team in planning for the sustain-
ability of the project and the long-term use of EPAD
samples and data.
Fig. 1 Overview of local and central participant panel set-up within the EPAD LCS study structure. Local panels were recruited from longitudinal
cohort participants. They worked with local study teams, and were represented on the central participant panel. This central panel fed directly
into the work of the EPAD ethics workgroup and the General Assembly of the project
Table 1 Overview of local and central panel set-up arrangements in the EPAD LCS study
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Local panels
Each country was given a mandate to establish partici-
pant involvement on either a research centre or country
level in the form of a panel. Whilst the common lan-
guage spoken at the central panel was English, requiring
a certain level of ability to speak English, the local panels
facilitated multi-lingual involvement with participants. A
terms of reference document was created as a guide for
research teams (Appendix One), however these terms
could be adapted as appropriate to meet local require-
ments and based on discussions with local panel mem-
bers. This discussion was a key stage in establishing and
managing the expectations of participants and re-
searchers about the participant panel role. We describe
below the set up and running of the panels with com-
monalities first described, followed by any unique adap-
tations made:
Scotland In Scotland there was an established centra-
lised country wide panel, with membership from four
recruiting centres (NHS Lothian, Grampian, Greater
Glasgow & Clyde and Tayside). The choice to form one
country wide panel was advocated for by the participant
members and worked well in a geographically small
country. Towards the end of the project a participant led
panel was also established in NHS Grampian. Panel
members from Grampian advocated for this due to
interest from their fellow participants in the area to con-
tribute their feedback to the panel without joining the
Scottish wide group.
England: Oxford, West London and Bristol England
similarly established a panel to represent participants
from multiple centres. The panel ran from Oxford, Eng-
land and involved participants from three centres (Ox-
ford, West London and Bristol).
The Netherlands: Amsterdam The panel in the
Netherlands was housed at the VuMC (Vrije Univercen-
treit Medical Centre). As there was only one centre in
the Netherlands this panel operated both as the country
and centre wide panel.
France: Toulouse France had one panel in operation,
based and run from the Toulouse centre. As one of the
largest centres in the EPAD study Toulouse was able to
harness the participant voice onto this panel.
Spain: Barcelona Spain’s panel was in Barcelona, the
first EPAD centre to open in Spain.
Establishing the panels
The panels were in operation for a range of time, with
the Scottish and Barcelona based panels established in
early 2017, and the newest panels, England and Tou-
louse, established in 2019. All panels have met at least
twice at the time of this paper.
Panels employed a variety of recruitment methods
during the initial set-up period, all of which were suc-
cessful. Three panels (Scotland, England and Toulouse)
contacted all local participants via letter or email to ex-
plain that a participant panel was being established and
asking for interested participants to contact the coordin-
ating centres to receive more information. In
Amsterdam the panel was first introduced during an an-
nual meeting for participants, to which all EPAD partici-
pants were invited, and the panel opportunity was
followed up during the dissemination of minutes from
this meeting. In order to maximise the engagement of
the participants and the output of the panel, the team in
Barcelona established a list of criteria for the selection of
the potential panel members such: proximity to the
centre, sex, age, English language level, motivation.
These were participants who had previously expressed
interest in being more involved in the study and each
participant was contacted by phone to assess interest in
joining the panel. Most panels enrolled people on a first
come first served basis, with the exception of Toulouse
which enrolled based on longevity in the EPAD study.
At the time of the cohort study closing a waiting list was
in operation at the Scottish, English, Toulouse and
Barcelona panels due to levels of demand. New recruits
were informed about the participant panel using flyers
in Scotland and via email in Barcelona, whilst
Amsterdam elected to maintain a static panel as the par-
ticipants involved have the most experience of the EPAD
study and were motivated to remain in the panel.
Scotland is a unique example in this group as it was ini-
tially established as an Edinburgh based panel and had
since expanded on the advice of the panel members to
include participants from all Scottish centres.
The initial meetings of each panel involved similar
agendas set by EPAD staff, with setting the scene and
explaining the purpose of the panel, establishing rules of
engagement around confidentiality and terms of refer-
ence for the panel, and nominating a participant as chair
of the panel. At the Barcelona and Toulouse panels, a
vice-chair was also selected to support with the leader-
ship of the panel.
Logistics of running the panel
The panels were all set up to run twice a year, with ad-
hoc contact in between for matters arising that are time
sensitive. The Barcelona panel met up to 4 times a year
on the request of the participant panel members. Num-
bers of panel members ranged from 7 at Amsterdam to
12 in the Scottish panel, with the group size aimed to be
large enough to capture a diversity of experience and
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opinions, whilst remaining small enough to allow every-
one time to meaningfully contribute to the meetings.
EPAD study staff were in attendance at every panel
meeting, and in most centres the Chief Investigator or
Principal Investigator also attends. The staff attended to
organise the logistics of the meeting, provide study up-
dates and answer specific questions from the panel, fa-
cilitate discussions if required and to minute the
meetings. Panels met at locations convenient for partici-
pants, travel expenses were provided alongside refresh-
ments, be that coffee or lunch depending on the
preferred time of the meeting at each centre. Communi-
cation varied between countries depending on formats
allowed under data protection laws, and included email,
post and closed WhatsApp groups.
Content of panel discussions
Panel meeting agendas were developed by the partici-
pants, led by the panel chair. Using the Scottish panel as
an example there were standing agenda items including
dementia moments (recent news stories about brain
health and dementia), an update on the study progress
to data (both internationally and for Scotland) and the
proof of concept trials. Additional topics were then
added to each meeting as desired by the participants.
Additional topics discussed by panels included sustain-
ability and longevity of the project, feedback on the
study visit (including experiences, practicalities and lo-
gistical aspects), documentation review and discussions
around receiving results on potential risk factors discov-
ered through the EPAD study.
Study advocacy and engagement
Panel members have attended a variety of events in
every country to speak about their involvement with
EPAD and contribute to meetings based on their experi-
ences both as participants and as panel members. These
include the IMI Stakeholder Forum 2017 where a par-
ticipant represented the EPAD study on a panel discus-
sion on PPPI, National Research Scotland (NRS) annual
meeting in Perth 2018 where two panellists co-authored
a poster about the panel, the EUPATI (European Pa-
tients Academy) 2018 meeting where two panellists
spoke about their involvement in EPAD, and co-hosting
a webinar to discuss the set up and running of a partici-
pant panel to support other centres considering hosting
a panel. The Scottish and English panels have both con-
tributed to the annual EPAD conferences held in these
countries where all centre staff gather to share experi-
ences with the study. The Barcelona panel are credited
by centre staff with raising the profile of Alzheimer’s dis-
ease research in the Catalonia region through their out-
reach activities.
Review of study documentation
Review of study documentation, including the study
website, has been an important role played by the panels,
helping to ensure any information provided to partici-
pants is understandable and appropriate for use. Sugges-
tions from the panel led to rewording of study
documents, improving readability and adapting images
used in videos. The feedback received on study docu-
mentation was described as ‘positive and constructive
criticism’ by staff. Many of the panels discussed protocol
amendments for their advice on local implementation of
changes and how best to communicate this to partici-
pants. One of these changes included the use of ani-
mated videos to support the consent process, which was
a new method of communication for most sites. By dis-
cussing amendments such as this with the panel, centre
staff felt confident in the protocol amendment roll-out
across the centre.
The Barcelona centre has developed videos with the
panel focusing on the mandatory lumbar puncture pro-
cedure in the study protocol. Perhaps unsurprisingly,
participant panel members in most countries discussed
experience of lumbar punctures and suggested improve-
ments for the information provided about these. From
these discussions the Spanish panel worked with the
Barcelona centre to develop two videos about the pro-
cedure, one describing the procedure and one providing
volunteers personal experience of undergoing the pro-
cedure. Participants were able to watch these videos
prior to the procedure as a communication mechanism
to support with the learning about the procedure, with
staff noting a a reduction in pre-procedural nerves for
some participants. This was a technique similarly used
in the UK based Deep and Frequent Phenotyping pilot
study where an explanatory video was produced in col-
laboration with the Alzheimer’s Society [32, 33]. In
Amsterdam, the panel initially fed back that they often
did not know whom they were seeing during their visit,
as the complex procedures required a large number of
staff to successfully deliver the study. Following this the
team introduced a ‘study card’ to better explain the lo-
gistics of the visit and the roles of the EPAD team mem-
bers involved, with the panel members collaborating on
the wording and presentation of this card. This simple
communication tool aimed to ensure that participants
have the knowledge they want and need about their
study visit, improving their overall experience at the
centre.
The study experience
Panel members discussed their recent study experiences
during their local panel meetings, which led to a number
of changes being enacted at centres. Some of the
changes were relatively minor, such as an improvement
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in signage to one of the Scottish centres. Communica-
tion between researchers and participants was a com-
mon theme with advice sought on how people wanted to
receive abnormal results discovered during the study
(such as abnormal blood pressure, blood results or mag-
netic resonance imaging (MRI) findings of clinical sig-
nificance). The preference from panel members was for
this to be done with a personal connection, either over
the phone or face to face, as opposed to receiving a letter
or email with the results. As such this method of feed-
back for clinically significant results was implemented.
Another communication change related to collection of
saliva samples, which involved a relatively complex
home collection method. After expressing some difficul-
ties with this collection sites were able to spend more
time discussing the instructions with the participants
and suggesting helpful reminders such as setting alarms
on a mobile phone for when the sample should be
collected.
While the study as a whole did not routinely commu-
nicate the results of cerebrospinal fluid (CSF) tests to
healthy participants, in Amsterdam the participant panel
advocated for disclosure of the CSF data on the explicit
request of the participant. This led to the development
of standard operating procedures to support with this,
and to the disclosure of amyloid status to 20 participants
based at the VuMC centre.
Study planning
Participant panel members from Scotland and
Amsterdam were invited to participate in a meeting to
plan the future of the EPAD study following the end of
the initial funding period. Prior to this meeting members
of the EPAD consortium (EPAD sites, academic and in-
dustry partners) had completed a survey to outline their
views on what EPAD should prioritise to continue in the
next stage of the project. During the meeting these sur-
vey responses were reviewed and a guidance document
produced to advise the EPAD Management team on the
next steps they should take and the possible outcomes
of how the study could function in the next phase. Panel
members were asked to attend to give a voice to the par-
ticipant experience and add their views to how EPAD
should evolve. Their views contributed to highlighting
areas of convergence and divergence between participant
and researcher perspectives, and to reinforcing the im-
portance of maximising long-term sustainability of the
study biobank and database.
Participant panel perspective
Members of the Scottish and Spanish participant panels
were asked by a panellist co-author to reflect on their
experiences of the panel and provide feedback for use in
this evaluation of the panel successes. All other panels
were able to get input from at least one participant panel
member. These experiences are reported below.
Prior to joining the panel, members had few expecta-
tions of what joining might mean, and there was some
doubt about how much ‘influence the participants would
have on the day-to-day workings of EPAD’. People did
anticipate that the meetings would be forums to ‘provide
feedback on our EPAD experiences’ and ‘the chance to get
to know other participants and to share experiences with
them’. Participants thought the panel would offer an av-
enue for collaboration and to spread the word about
both EPAD and Alzheimer’s disease. Panel members
were often motivated to join the panel by their personal
experiences of living with parents with dementia.
Considering the set-up of the meetings, panel mem-
bers felt there was a ‘nice balance’ of a structured ap-
proach that remained ‘flexible as the agenda is set by the
participants in conjunction with EPAD staff’. Members
appreciated the attendance of staff members who are
‘aware of the items on the agenda … and know the out-
come of each discussion’. They report the meetings as ‘in-
clusive’, with a pleasant working atmosphere, and the
Scottish group in particular note that ‘the fact that [the
Principal Investigator] takes the time to come to meetings
is hugely empowering’. These experiences demonstrate
the importance of providing resources to participant
groups to ensure efficient operation and maintaining an
informal and flexible meeting style to encourage all par-
ticipants to voice their experiences and opinions. In
some centres participants advocated for more regular
meetings. This led to conflicts between the ambitions of
the panel and desire for increased regularity of meetings,
against the limits of resources the research team have to
allocate. The Barcelona team had been able to support
an increase in regularity of meetings, whilst other cen-
tres maintained a six-monthly schedule. Other centres
were able to discuss the limitations of resource and
agree with the panel that meeting twice a year would be
acceptable.
Panel members reflected staff views that their input
had helped to improve the participant experience by
providing ‘a forum for participants to have their concerns
voiced and attended to’ which has made the yearly visits
to study centres ‘as comfortable as possible’. Importantly
the panel members were key decisions makers in ‘the de-
cision to have a Scottish panel rather than a participant
panel for each Scottish trial delivery centre’. By combin-
ing the collective experiences from these centres it is
likely the panel has been able to have a bigger impact
than that of four individual panels. They felt that it is
clear that the Scottish Participant Panel has ‘done a
great deal to publicise the study, to disseminate the Scot-
tish experience and to learn from what’s happening in
other countries’. The panel has managed to solidify
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participants as stakeholders in EPAD, by ‘reinforcing (sic)
their importance in the scheme of things’ and demon-
strating the ‘humanity of EPAD’. Participant panel mem-
bers felt they had contributed to ‘the transition from
EPAD to EPAD2’, which relates to sustainability discus-
sions about the long term goals of the project, in which
the participant voice has been invaluable. Panel mem-
bers reported attending numerous events but by meeting
other panel member groups from across Europe at the
EPAD General Assembly, the groups ‘had found a voice’.
One panel has the slogan ‘we want to be part of the solu-
tion’ and this ethos is clearly reflected in many of the
EPAD participant panels.
Discussions were held in panels to develop strategies
to make sure ‘everyone’s voices [are] heard by the re-
search team’, not just those who were panel members.
As part of this the Scottish group set up a satellite par-
ticipant led group in Aberdeen which fed into the coun-
try wide panel.
Discussion
The EPAD participant panel model proved beneficial to
the set-up, running and future of the EPAD project, in-
cluding participants as key stakeholders in the research.
A key feature of the participant panels has been that
they aim to be both participant-centred and, wherever
possible, participant-led. Thus, the aim has been to cre-
ate spaces for participant involvement and to establish
the remit and scope of this involvement through on-
going dialogue between researchers and participants.
The panels were established using overarching terms of
reference that mandated meetings that were participant-
led and held at least twice a year. Each centre then de-
veloped and adapted the set-up in line with the needs
and expectations of local panel members. Overall, the
panels have many similarities, with meetings chaired by
a participant member and EPAD staff in attendance to
organise and minute meetings. A member of staff at
each site was responsible for liaising with the panels,
with the EPAD ethics group co-ordinating the central
panel meeting. Some differences arose in how regularly
panels meet and how panels communicate between face
to face meetings. The panels have been able to achieve
success in affecting how the study is run in the local
centres, provide support on documentation, advocate for
the study at local, national and international meetings,
and provide opinion on the future directions that EPAD
should take.
Strengths
We believe this nested participant panel model is
adaptable for use in multi-national cohort settings.
PPI can often focus on involving people living with a
particular disease, who often are not directly enrolled
as participants in the research project [34]. This
works well in these areas because there is an identifi-
able group of people to approach as PPI members.
However when we consider long-term research with
the general population, or even ‘at risk’ groups, we
need to be more creative in recognising both the
commitment that individuals make to such research,
and the experience and knowledge they acquire
through participation. Our experience suggests
though, that such panels benefits from clear responsi-
bilities for planning and outlining the reasons for par-
ticipant involvement activities, the availability of
sufficient budget and a common but adaptable frame-
work that allows expectations to be established and
managed [34].
Benefits of participant involvement in the EPAD study
have been reported by both panel members and re-
searchers. Participant panel members felt they had a
voice as part of the research team by being involved in
panel activities, and that this was an empowering experi-
ence. Empowerment has been identified as an important,
but poorly reported, potential outcome of PPPI work
[35] and it is encouraging to see panel members report-
ing this. Panel members reflected that they had been
able to influence EPAD to make study visits as comfort-
able for fellow participants as possible, felt they had con-
tributed to the study by discussing it in public facing
forums, and had introduced a reminder of the lived ex-
perience of research participation when study leadswere
considering strategic decisions about the next steps for
the EPAD project. Minute taking in meetings, and the
identification of clear tasks and actions for members of
the research team, enabled the panels to have meaning-
ful and traceable impact on the development of the
study, created accountability within the local study cen-
tres and helped prevent involvement becoming ‘tokenis-
tic’. This was further facilitated by the identification of
individuals within the research team at each centre re-
sponsible for liaising with the participant panel.
By involving participants, rather than interested mem-
bers of the public, EPAD benefited from ongoing advice
given by participants with direct experience. This has
meant other participants in the study were also able to
benefit in the immediate term, as opposed to just future
participants potentially benefiting from participant panel
advice. The panels influenced the design and impact of
the research, which INVOLVE suggest contributes to
the quality of the study [17]. Panel feedback on the ex-
perience of taking part in the EPAD study, and interest
in the extent to which their experience was representa-
tive of the wider study population contributed to the de-
velopment of a mixed-methods sub-study of participant
experience across the EPAD centres. This study is cur-
rently in analysis and write-up.
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Challenges
There are, however, challenges to be considered by re-
searchers when establishing panels. Due to the time
spent setting up the panel and learning from the estab-
lishment of the PREVENT Dementia panel, the EPAD
panels have largely managed to avoid these pitfalls.
Challenges at the central panel level have included the
time commitment of participants and resourcing of
travel for non-research staff to attend annual meetings
held across Europe and the challenge of explicitly in-
corporating a participant role into pre-defined govern-
ance structures. Ensuring sufficient budget is available
for PPI activities has been recognised as a key consider-
ation for success [34, 36] [INSERT REF], and this is also
the case for participant involvement activities.
The panels have not always moved in line with initial
researcher expectations. For example, while the initial
plan for participant representation included representa-
tion on study governance committees, and provision was
made for this, participants at central panel meetings
concluded that involvement in the General Assembly as
part of the EPAD research community, and direct inter-
action with study leads through the local panels, pro-
vided a sufficient level of input into overall and local
project decision-making.
The participant-led nature of the panels created the
potential for conflicts between the ambitions of the
panel and the realities of what the research staff can
deliver. Others have noted the importance of identify-
ing and addressing differences in assumptions be-
tween what staff want to achieve and what PPPI
members want to achieve [37]. EPAD panels encour-
aged open and transparent dialogue during panel set-
up and throughout the involvement process, with dis-
cussions on what actions could and would or would
not be taken, with discussion of the reasons. Estab-
lishing these expectations helped with panel cohesion
and understanding of role panel responsibilities
among study researchers.
Structured training was not provided to either panel
members or the staff facilitating panels. On reflection
this is an area which we would develop in future work,
to ensure all parties had a shared skill set and under-
standing of the participant involvement process. Train-
ing sessions for staff would include developing a shared
view of the value of a shift to an equal relationship, the
importance of reducing the use of technical language
and how to recruit participant panel members, as iden-
tified in previous studies of PPI in UK clinical trials
[38]. Training for panel members could focus on adapt-
ing their skill set to the research context as suggested
in INVOLVE training support guidelines [39]. Again,
however, it is important to consider the challenges as-
sociated with delivering such training across countries,
in multiple languages, and the resources associated with
this.
Particular challenges related to the area of research
and the scope of the study. The first was the recruit-
ment of a group of participants across the diagnostic
spectrum involved in the cohort study, which re-
cruited both healthy volunteers and people with mild
cognitive impairment. In the panel the aim was to
capture a variety of voices to represent the spectrum
of experiences in the EPAD study. However, the panel
members at all centres were for the most healthy vol-
unteers rather than participants with mild cognitive
impairments. One of the contributors to this imbal-
ance was that the original participant recruitment to
the study was biased towards healthy volunteers and
as such when the panels were established the majority
of participants invited to join were cognitively healthy.
As such there was a group of participants in the
EPAD LCS cohort who were currently not well repre-
sented in the panel memberships. Reasons for this
difficulty in engagement, reported by the staff in-
volved in supporting the panels, include both re-
searcher bias about burdening patient participants,
participant confidence in attending an unfamiliar en-
vironment and logistics of attending for someone who
may prefer to have a study partner with them. Other
than cognitive impairment the panels reflected the
study participants well, with diversity reflected in
multiple European panels. We also note that the aim
of PPI work is not to have a representative sample,
rather to have input from participants who reflect the
diversity of the cohort. Future work in this area
should consider ways to tackle inequity of diversity of
cognitive impairment in participant representation so
as to ensure equality with regard to actual involve-
ment [40].
Data gathered for this paper was done in an infor-
mal manner after staff reflected that the panels had
been successful and sharing the story may benefit
others. While we feel that we have been able to pro-
vide a good overview of the panels, we did not have
pre-set objective measures of success against which to
measure the panels. Setting up clearly defined, achiev-
able, measurable outcomes from the start may help to
monitor the success of planned participant involve-
ment activities. This would support development of
an evidence base that is data driven, which is cur-
rently lacking as shown by recent systematic reviews
[41]. However, in a context that aims to be
participant-led and multinational, it is also important
that any such evaluation is both responsive and
adaptable to both participant values and the place of
involvement activities in local research practice and
governance frameworks.
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Recommendations
We believe the model employed in the EPAD study is
adaptable to other projects, both at international levels
and with other long-term research populations. We have
developed a series of recommendations for other re-
searchers below.
Recommendation One: Develop central terms of refer-
ence to establish core values and goals across all panels,
but allow local adaptations to foster participant owner-
ship of their group.
Recommendation Two: Empower and support partici-
pants to chair meetings and use staff in support roles, to
ensure the meetings are participant-led but not burden-
some for participant members from an organisation
perspective.
Recommendation Three: Ensure sufficient budget is
allowed for participant involvement activities.
Recommendation Four: Identify training needs, both
for participant members and staff, to support engage-
ment with the participant panel.
Recommendation Five: Establish how outcomes for
participant involvement will enable success to be moni-
tored against the goals established by participants.
Conclusion
The EPAD participant panel model has shown that large
scale participant involvement can be successfully con-
ducted in a multi-centre, pan-European study, working
across multiple languages, and with the goals and direc-
tion of involvement led, in large part, by participants
themselves. While such a participant-led approach can
present challenges to both researchers and participants,
it ensures that the panels are reflective of and responsive
to, the needs and concerns of participants themselves.
We believe this is a model that can be adapted to suit
similar study populations.
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